Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays

Yusheng Qu., Robert Kirby., Richard Davies., Ayesha Jinat., Stefano Stabilini., Bin Wu., Longchuan Yu., BaoXi Gao., and Hugo M. Vargas. (2023). Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays. Nucleic Acid Therapeutics. Nucleic Acid Therapeutics, 2022.

This publication was awarded the '2024 Technology Innovation Publication Award' by the Safety Pharmacology Society.


View
Recommended Publications
Latest Publications
Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806

NS5806, widely used as a Kv4-selective activator, also activates TREK-1 and TREK-2 potassium channels.

Beyond Hybridisation: Biologically Meaningful Protein Interactions of Oligonucleotides

Nature Communications paper ‘The nucleobase guanine at the 3′-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity'

View All
Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806
Future-proof cardiac safety: Scalable hiPSC cardiomyocyte new approach methodologies (NAMs) that de-risk earlier and strengthen IND packages
View All
Metrion is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram